View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 10, 2020

African Union Commission launches Covid-19 vaccine trial consortium

The African Union Commission has introduced the new Africa Centres for Disease Control and Prevention (Africa CDC) Consortium for COVID-19 Vaccine Clinical Trial (CONCVACT).

The African Union Commission has introduced the new Africa Centres for Disease Control and Prevention (Africa CDC) Consortium for COVID-19 Vaccine Clinical Trial (CONCVACT).

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

CONCVACT is part of the Africa Joint Continental Strategy for tackling Covid-19. The goal is to prevent severe Covid-19 illness and deaths in African Union Member States, reduce social disruption, and minimise the economic consequences of the pandemic.

A vaccine is expected to limit transmission, prevent deaths, and support socio-economic recovery in Africa.

South Africa President Cyril Ramaphosa said: “Success in developing and providing access to a safe vaccine requires an innovative and collaborative approach, with significant local manufacturing in Africa.

“We need to support the contribution of African scientists and healthcare professionals. We need to act with urgency.”

CONCVACT plans to secure more than ten late-stage vaccine trials at the earliest via collaborations with global vaccine developers and funders, and African firms that enable clinical studies.

The consortium hopes to capture the safety and efficacy data of promising vaccine candidates for the African population in order to validate their launch after approval.

It will establish an independent review board for guidance, assistance and oversight of trials, as well as work to increase public awareness on clinical testing in the continent.

African Union Commission Social Affairs Commissioner Amira Elfadil Mohammed said: “There is urgent need for global solidarity, cooperation, and appropriate regulation to ensure equitable access to potential Covid-19 vaccine.

“The African Union will continue to partner with GAVI, WHO and other relevant stakeholders in the development of Covid-19 vaccine.”

Last month, the University of Witwatersrand in South Africa collaborated with the UK’s University of Oxford and the Oxford Vaccine Group to evaluate a Covid-19 vaccine candidate developed at the UK university.

This marks South Africa’s first trial of a vaccine against Covid-19.

If the vaccine trial is successful, Africa expects a Covid-19 vaccine to be available in the first quarter of next year, reported Reuters, citing a University of Witwatersrand professor.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena